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population (including 27 patients without heartburn
symptoms). Correlations were also assessed for each 
category of symptom severity in patients with heart-
burn (mild, n = 30; moderate, n = 64; severe, n = 15).
RESULTS: The correlation between PW and PA was
found to be high and statistically signiﬁcant (PCC 0.82,
p < 0.0001). This ﬁnding was consistent in patients with
either mild, moderate or severe heartburn. A positive rela-
tionship was also found between AW and PW (PCC 0.57,
p < 0.0001), as well as between AW and PA (PCC 0.52,
p < 0.0001). The PCC between AW and PW increased
with heartburn severity (mild: -0.19, moderate: 0.48,
severe: 0.78), since the proportion of patients reporting
any absence from work increased with heartburn sever-
ity (mild: 7%, moderate: 28%, severe: 33%). Thus,
results indicate that in patients with moderate or severe
heartburn, absence from work is also associated with
reduced productivity while at work. CONCLUSIONS:
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OBJECTIVES: In 2001, the Veterans Affairs Healthcare
System implemented a proton pump inhibitor (PPI) con-
version to rabeprazole in patients who were previously
on either omeprazole or lansoprazole. An unpublished
study by Humphries and colleagues showed that rabepra-
zole, when taken concomitantly with digoxin, increased
the digoxin trough level by 22%, AUC by 19%, and
Cmax by 29%. Safety during the conversion of patients
already taking digoxin and a PPI chronically was uncer-
tain. Therefore, a medical center observational, nonran-
domized prospective drug utilization evaluation (DUE)
was designed to ensure safety throughout the conversion
process. METHODS: One hundred and twelve patients
were identiﬁed via prescription data base search. Pre- and
post-digoxin levels were drawn to assess for the potential
drug interaction and toxicity associated with the switch
from lansoprazole or omeprazole to rabeprazole. Levels
were scheduled for baseline and 7–10 days following 
conversion to rabeprazole. All patients were converted 
to rabeprazole upon clinic visit through pharmacist 
intervention. Adverse effects were monitored at conver-
sion and during follow-up visit. RESULTS: Forty-seven
patients completed the DUE conversion project. Mean
pre-and post-digoxin levels were 0.85 ± 0.93ng/ml and
0.86 ± 0.51ng/ml, respectively (p = 0.93). Twelve patients
had digoxin levels elevated more than 15%, 3 of whom
were symptomatic. CONCLUSIONS: A statistically sig-
niﬁcant drug interaction was not observed. However, due
to absence of a control group in this DUE, we recommend
baseline digoxin levels and patient education of potential
signs and symptoms of digoxin toxicity to ensure safety
during a medication conversion. It does not appear 
that post-conversion digoxin levels are warranted unless
accompanied by signs and symptoms of toxicity.
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OBJECTIVES: Proton pump inhibitors (PPIs) are potent
gastric acid suppressants. They have been widely 
prescribed for various acid-related disorders. In 2000/01,
omeprazole and lansoprazole were PPIs available in the
Pamela Youde Nethersole Eastern Hospital (PYNEH) and
the consumption of PPIs accounted for HK$3.4 millions
(US$1 = HK$7.8), which was 3% of the total drug expen-
diture of the hospital. A drug utilization evaluation of
PPIs was carried out to estimate the impact of unlicensed
uses of PPIs on the overall drug expenditure in this local
public hospital. METHOD: A retrospective study was
performed on patients admitted to the PYNEH. The study
cohort consisted of all inpatients (excluding intensive care
patients) and outpatients who were aged 18-year old or
above and were dispensed PPIs for seven days or more
(except for those on intravenous route PPIs) between 1
January and 30 June 2001. Two hundred and four patient
medical charts were randomly selected from the cohort.
Clinical and laboratory data were collected from the
medical records. RESULTS: After reviewing 204 patient
records, 185 (90.7%) prescriptions of PPIs were complied
with the licensed indications. Of the 19 prescriptions of
unlicensed uses, 9 (47.4%) and 4 (21.1%) prescriptions
were for treatment of gastritis and/or duodenitis and 
for empirical treatment of epigastric pain respectively.
The drug cost-avoidance of unlicensed uses of PPI was
HK$19,477.6. Data collected during this 6-month period
were extrapolated to one year, the projected annual pos-
sible cost-avoidance of unlicensed uses would be approx-
imately HK$400,000 which accounts for 0.35% of the
total drug expenditure. CONCLUSION: This study con-
cluded that the compliance rate of licensed indications of
PPIs was high but the unlicensed uses still resulted in a
signiﬁcant drug cost-avoidance. Educational programs
may be designed to reduce the incidence of unlicensed
uses and thus to reduce the associated costs in the future.
